- Current report filing (8-K)
June 30 2010 - 8:30AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
June 15,
2010
ImmunoGen, Inc.
(Exact name of registrant as specified in its charter)
Massachusetts
|
|
0-17999
|
|
04-2726691
|
(State or other
jurisdiction of
incorporation)
|
|
(Commission File
Number)
|
|
(IRS Employer
Identification No.)
|
830 Winter Street, Waltham, MA 02451
(Address of principal executive offices) (Zip Code)
Registrants telephone number, including area code:
(781) 895-0600
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (
see
General
Instruction A.2. below):
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION
OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF
CERTAIN OFFICERS
(a)
(d) Not applicable.
(e)
On June 15, 2010, the Compensation Committee of the Board of Directors of
ImmunoGen, Inc. (the Company) increased the target bonus for Mr. Daniel M.
Junius, the Companys President and Chief Executive Officer, under the Companys
annual executive bonus program from 45% to 50% of his annual base salary,
beginning with the Companys fiscal year 2011 starting on July 1, 2010. The Committee also determined to leave the
target bonuses for the Companys other executive officers unchanged from the
previous year.
(f)
Not applicable
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ImmunoGen, Inc.
|
|
(Registrant)
|
|
|
Date:
June 30, 2010
|
/s/
Gregory D. Perry
|
|
|
|
Gregory
D. Perry
|
|
Senior
Vice President and Chief Financial Officer
|
2
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Oct 2023 to Oct 2024